ArticleNeurology2018
Age-accelerated cognitive decline in asymptomatic adults with CSF β-amyloid.
Open access · bronzeAbstract read
In one paragraph
Article in Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
6.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Association between amyloid-β deposition and cognitive function in cognitively normal adults: a multilevel meta-analysis.Alzheimer's research & therapy · 2026Pooled it
- Cross-sectional associations of amyloid burden with semantic cognition in older adults without dementia: A systematic review and meta-analysis.Mechanisms of ageing and development · 2020Pooled it
- Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis.Alzheimer's research & therapy · 2019Pooled it
- Telomere Length and Cognitive Function Among Middle-Aged and Older Participants From Communities Underrepresented in Aging Research: A Preliminary Study.Journal of aging and health · 2026Article
- Whole genome methylation sequencing in blood from persons with mild cognitive impairment and dementia due to Alzheimer's disease identifies cognitive status.bioRxiv : the preprint server for biology · 2024Article
- Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies.Translational neurodegeneration · 2024Review
- Alzheimer's Disease: A Review of Pathology, Current Treatments, and the Potential Therapeutic Effect of Decreasing Oxidative Stress by Combined Vitamin D and l-Cysteine Supplementation.Antioxidants & redox signaling · 2024Review
- Whole genome methylation sequencing in blood identifies extensive differential DNA methylation in late-onset dementia due to Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Neurophysiological markers of early cognitive decline in older adults: a mini-review of electroencephalography studies for precursors of dementia.Frontiers in aging neuroscience · 2024Review
- Associations between recall of proper names in story recall and CSF amyloid and tau in adults without cognitive impairment.Neurobiology of aging · 2024Article
- Article
- Article
- The protective effects of Agomelatine against Aβ1-42 oligomers-induced cellular senescence mediated by SIRT6 and Agomelatine's potential in AD treatment.Human cell · 2021Article
- In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease.Alzheimer's research & therapy · 2021Article
- Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults.Alzheimer's research & therapy · 2021Article
- Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age.Neurobiology of aging · 2021Article
- Association of Neighborhood Context, Cognitive Decline, and Cortical Change in an Unimpaired Cohort.Neurology · 2021Article
- Pilot proteomic analysis of cerebrospinal fluid in Alzheimer's disease.Proteomics. Clinical applications · 2021Article
- Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease.Neurology · 2021Article
- Amyloid-β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old.Annals of clinical and translational neurology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 2 countries.
Lindsay R ClarkFrom the Geriatric Research Education and Clinical Center (L.R.C., S.A., S.C.J., C.M.C.), William S. Middleton Memorial Veterans Hospital, Madison; Alzheimer's Disease Research Center (L.R.C., S.E.B., D.N., B.B.B., S.A., S.C.J., C.M.C.), Wisconsin Alzheimer's Institute (L.R.C., R.L.K., E.J., B.B.B., S.C.J., C.M.C.), Medical Scientist and Neuroscience Training Programs (S.E.B.), and Department of Biostatistics and Medical Informatics (D.N.), University of Wisconsin-Madison School of Medicine and Public Health; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and Department of Molecular Neuroscience (H.Z.), University College London, Institute of Neurology, Queen Square, London, UK. lrclark@medicine.wisc.edu.
Sara E BermanFrom the Geriatric Research Education and Clinical Center (L.R.C., S.A., S.C.J., C.M.C.), William S. Middleton Memorial Veterans Hospital, Madison; Alzheimer's Disease Research Center (L.R.C., S.E.B., D.N., B.B.B., S.A., S.C.J., C.M.C.), Wisconsin Alzheimer's Institute (L.R.C., R.L.K., E.J., B.B.B., S.C.J., C.M.C.), Medical Scientist and Neuroscience Training Programs (S.E.B.), and Department of Biostatistics and Medical Informatics (D.N.), University of Wisconsin-Madison School of Medicine and Public Health; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and Department of Molecular Neuroscience (H.Z.), University College London, Institute of Neurology, Queen Square, London, UK.
Derek NortonFrom the Geriatric Research Education and Clinical Center (L.R.C., S.A., S.C.J., C.M.C.), William S. Middleton Memorial Veterans Hospital, Madison; Alzheimer's Disease Research Center (L.R.C., S.E.B., D.N., B.B.B., S.A., S.C.J., C.M.C.), Wisconsin Alzheimer's Institute (L.R.C., R.L.K., E.J., B.B.B., S.C.J., C.M.C.), Medical Scientist and Neuroscience Training Programs (S.E.B.), and Department of Biostatistics and Medical Informatics (D.N.), University of Wisconsin-Madison School of Medicine and Public Health; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and Department of Molecular Neuroscience (H.Z.), University College London, Institute of Neurology, Queen Square, London, UK.
Rebecca L KoscikFrom the Geriatric Research Education and Clinical Center (L.R.C., S.A., S.C.J., C.M.C.), William S. Middleton Memorial Veterans Hospital, Madison; Alzheimer's Disease Research Center (L.R.C., S.E.B., D.N., B.B.B., S.A., S.C.J., C.M.C.), Wisconsin Alzheimer's Institute (L.R.C., R.L.K., E.J., B.B.B., S.C.J., C.M.C.), Medical Scientist and Neuroscience Training Programs (S.E.B.), and Department of Biostatistics and Medical Informatics (D.N.), University of Wisconsin-Madison School of Medicine and Public Health; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and Department of Molecular Neuroscience (H.Z.), University College London, Institute of Neurology, Queen Square, London, UK.
Erin JonaitisFrom the Geriatric Research Education and Clinical Center (L.R.C., S.A., S.C.J., C.M.C.), William S. Middleton Memorial Veterans Hospital, Madison; Alzheimer's Disease Research Center (L.R.C., S.E.B., D.N., B.B.B., S.A., S.C.J., C.M.C.), Wisconsin Alzheimer's Institute (L.R.C., R.L.K., E.J., B.B.B., S.C.J., C.M.C.), Medical Scientist and Neuroscience Training Programs (S.E.B.), and Department of Biostatistics and Medical Informatics (D.N.), University of Wisconsin-Madison School of Medicine and Public Health; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and Department of Molecular Neuroscience (H.Z.), University College London, Institute of Neurology, Queen Square, London, UK.
Kaj BlennowFrom the Geriatric Research Education and Clinical Center (L.R.C., S.A., S.C.J., C.M.C.), William S. Middleton Memorial Veterans Hospital, Madison; Alzheimer's Disease Research Center (L.R.C., S.E.B., D.N., B.B.B., S.A., S.C.J., C.M.C.), Wisconsin Alzheimer's Institute (L.R.C., R.L.K., E.J., B.B.B., S.C.J., C.M.C.), Medical Scientist and Neuroscience Training Programs (S.E.B.), and Department of Biostatistics and Medical Informatics (D.N.), University of Wisconsin-Madison School of Medicine and Public Health; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and Department of Molecular Neuroscience (H.Z.), University College London, Institute of Neurology, Queen Square, London, UK.
Barbara B BendlinFrom the Geriatric Research Education and Clinical Center (L.R.C., S.A., S.C.J., C.M.C.), William S. Middleton Memorial Veterans Hospital, Madison; Alzheimer's Disease Research Center (L.R.C., S.E.B., D.N., B.B.B., S.A., S.C.J., C.M.C.), Wisconsin Alzheimer's Institute (L.R.C., R.L.K., E.J., B.B.B., S.C.J., C.M.C.), Medical Scientist and Neuroscience Training Programs (S.E.B.), and Department of Biostatistics and Medical Informatics (D.N.), University of Wisconsin-Madison School of Medicine and Public Health; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and Department of Molecular Neuroscience (H.Z.), University College London, Institute of Neurology, Queen Square, London, UK.
Sanjay AsthanaFrom the Geriatric Research Education and Clinical Center (L.R.C., S.A., S.C.J., C.M.C.), William S. Middleton Memorial Veterans Hospital, Madison; Alzheimer's Disease Research Center (L.R.C., S.E.B., D.N., B.B.B., S.A., S.C.J., C.M.C.), Wisconsin Alzheimer's Institute (L.R.C., R.L.K., E.J., B.B.B., S.C.J., C.M.C.), Medical Scientist and Neuroscience Training Programs (S.E.B.), and Department of Biostatistics and Medical Informatics (D.N.), University of Wisconsin-Madison School of Medicine and Public Health; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and Department of Molecular Neuroscience (H.Z.), University College London, Institute of Neurology, Queen Square, London, UK.
Sterling C JohnsonFrom the Geriatric Research Education and Clinical Center (L.R.C., S.A., S.C.J., C.M.C.), William S. Middleton Memorial Veterans Hospital, Madison; Alzheimer's Disease Research Center (L.R.C., S.E.B., D.N., B.B.B., S.A., S.C.J., C.M.C.), Wisconsin Alzheimer's Institute (L.R.C., R.L.K., E.J., B.B.B., S.C.J., C.M.C.), Medical Scientist and Neuroscience Training Programs (S.E.B.), and Department of Biostatistics and Medical Informatics (D.N.), University of Wisconsin-Madison School of Medicine and Public Health; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and Department of Molecular Neuroscience (H.Z.), University College London, Institute of Neurology, Queen Square, London, UK.
Henrik ZetterbergFrom the Geriatric Research Education and Clinical Center (L.R.C., S.A., S.C.J., C.M.C.), William S. Middleton Memorial Veterans Hospital, Madison; Alzheimer's Disease Research Center (L.R.C., S.E.B., D.N., B.B.B., S.A., S.C.J., C.M.C.), Wisconsin Alzheimer's Institute (L.R.C., R.L.K., E.J., B.B.B., S.C.J., C.M.C.), Medical Scientist and Neuroscience Training Programs (S.E.B.), and Department of Biostatistics and Medical Informatics (D.N.), University of Wisconsin-Madison School of Medicine and Public Health; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and Department of Molecular Neuroscience (H.Z.), University College London, Institute of Neurology, Queen Square, London, UK.
Cynthia M CarlssonFrom the Geriatric Research Education and Clinical Center (L.R.C., S.A., S.C.J., C.M.C.), William S. Middleton Memorial Veterans Hospital, Madison; Alzheimer's Disease Research Center (L.R.C., S.E.B., D.N., B.B.B., S.A., S.C.J., C.M.C.), Wisconsin Alzheimer's Institute (L.R.C., R.L.K., E.J., B.B.B., S.C.J., C.M.C.), Medical Scientist and Neuroscience Training Programs (S.E.B.), and Department of Biostatistics and Medical Informatics (D.N.), University of Wisconsin-Madison School of Medicine and Public Health; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital, Mölndal; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and Department of Molecular Neuroscience (H.Z.), University College London, Institute of Neurology, Queen Square, London, UK.
United States Nuclear Regulatory Commission · US
Funding
Wisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA MethylationR01AG027161 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Nathaniel Ark Chin, Sterling C Johnson · 2007 to 2026
$35.6MInstitutional Clinical and Translational Science AwardUL1TR000427 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$32.2MThe Longitudinal Course of Neural Function and Amyloid in People At Risk for ADR01AG021155 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sterling C Johnson · 2004 to 2026
$27.0MWisconsin Alzheimer's Disease Research CenterP50AG033514 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI KIND, AMY J. · 2009 to 2018
$16.2MINTEGRATED TRAINING FOR PHYSICIAN-SCIENTISTST32GM008692 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BURKARD, MARK E · 1998 to 2020
$10.3MNEUROSCIENCE TRAINING PROGRAMT32GM007507 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI HALLORAN, MARY C · 1985 to 2017
$9.3MWhite matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR01AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2012 to 2023
$5.3MWhite matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR56AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2017 to 2017
$759kTwo Diseases or one? The early pathogenesis of vascular mediated cognitive decline and Alzheimer's Disease.F30AG054115 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BERMAN, SARA ELIZABETH · 2016 to 2019
$166kNCATS NIH HHS UL1 TR000427NIA NIH HHS F30 AG054115NIA NIH HHS P50 AG033514NIA NIH HHS R01 AG021155NIA NIH HHS R01 AG027161NIA NIH HHS R01 AG037639NIA NIH HHS R56 AG037639NIGMS NIH HHS T32 GM007507NIGMS NIH HHS T32 GM008692
Abstract
objectiveCompare cognitive and hippocampal volume trajectories in asymptomatic middle-aged and older adults with positive CSF markers of β-amyloid (Aβ) or tau to adults without an Alzheimer disease (AD)-associated biomarker profile.
methodsThree hundred ninety-two adults enrolled in a longitudinal cohort study (Wisconsin Registry for Alzheimer's Prevention or Wisconsin Alzheimer's Disease Research Center) completed a lumbar puncture and at least 2 biennial or annual neuropsychological evaluations. Cutoffs for Aβ
resultsTwo hundred fifteen participants (69%) were biomarker negative (preclinical AD stage 0), 46 (15%) were Aβ+ only (preclinical AD stage 1), 25 (8%) were Aβ+ and tau+ (preclinical AD stage 2), and 28 (9%) were tau+ only. Both stage 1 and stage 2 groups exhibited greater rates of linear decline on story memory and processing speed measures, and nonlinear decline on list-learning and set-shifting measures compared to stage 0. The tau+ only group did not significantly differ from stage 0 in rates of cognitive decline.
conclusionIn an asymptomatic at-risk cohort, elevated CSF Aβ (with or without elevated tau) was associated with greater rates of cognitive decline, with the specific pattern of decline varying across cognitive measures.
Indexed as
AgedAged, 80 and overAgingAmyloid beta-PeptidesBiomarkersCognitive DysfunctionDisease ProgressionHumansLongitudinal StudiesMiddle AgedPhosphorylationProdromal SymptomsRisktau ProteinsAmyloid beta-PeptidesBiomarkersMAPT protein, humantau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.